ALK increases sales in Q2, but operating result decreases

Wednesday morning, allergy company ALK presented the full report for the year's second quarter. The central figures were known ahead of time, since the company upgraded its guidance on Monday.

Photo: ALK / PR

Wednesday morning, pharmaceutical company ALK shed light on the last unknown figures in the company's Q2 report. Since the firm published the main figures for the quarter on Monday, there were no great surprises.

A combination of advancing sales, savings on certain expenses and delayed developmental activities meant that ALK, which specializes in allergies, increased the guidance for its revenue and earnings in all of 2021. Now, the firm expects its revenue will grow between 10-12 percent, and that its earnings before interest, taxes, depreciations and amortizations (EBITDA) will land in the interval DKK 450-500m (USD 70.8-78.7m), up against the previous DKK 375-425m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs